The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Open accessAbstract
SUMMARY Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has recently provided breakthrough progress in the treatment of melanoma, non-small cell lung cancer, and other types of cancer. Small-molecule drugs interfering with this pathway are highly awaited, but their development is hindered by insufficient structural information. This study reveals the molecular details of the human PD-1/PD-L1 interaction based on an X-ray structure of the complex. First, it is shown that the ligand binding to human PD-1 is associated with significant plasticity within the receptor. Second, a detailed molecular map of the interaction surface is provided, allowing definition of the regions within both interacting partners that may likely be targeted by small molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Scaling and assessment of data quality
Evans, P. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905036693 · Cited by 4,374
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The PD-1/PD-L1 interaction inhibits T-lymphocyte proliferation, release of cytokines, and cytotoxicity, resulting in exhaustion and apoptosis of tumorspecific T cells (Wherry, 2011).”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Schanda, P., & Brutscher, B. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051306e · Cited by 693
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 489
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · cited 1×
“Thereby, under normal conditions, the PD-1/PD-L1 pathway prevents excessive stimulation and maintains the immune tolerance to self-antigens by negatively regulating the immune response (Riella et al., 2012).”
BackgroundInman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
Schwartz, J.-C. D., Zhang, X., Fedorov, A. A., Nathenson, S. G., & Almo, S. C. (2001) · Nature · doi:10.1038/35069112 · Cited by 349
Muenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 334
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 323
XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS
Krug, M., Weiss, M. S., Heinemann, U., & Mueller, U. (2012) · Journal of Applied Crystallography · doi:10.1107/s0021889812011715 · Cited by 306
Mueller, U., Förster, R., Hellmig, M., Huschmann, F. U., Kastner, A., Malecki, P., Pühringer, S., Röwer, M., Sparta, K., Steffien, M., et al. (2015) · The European Physical Journal Plus · doi:10.1140/epjp/i2015-15141-2 · Cited by 299
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Self-citationAnti-programmed cell death protein-1/ligand-1 therapy in different cancers
Homet Moreno, B., & Ribas, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.124 · Cited by 245
Experiences in fragment-based drug discovery
Murray, C. W., Verdonk, M. L., & Rees, D. C. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.006 · Cited by 238
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 206
PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
Sun, S., Fei, X., Mao, Y., Wang, X., Garfield, D. H., Huang, O., Wang, J., Yuan, F., Sun, L., Yu, Q., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1519-x · Cited by 160
Biomarkers in Cancer Immunotherapy
Schumacher, T. N., Keşmir, C., & van Buuren, M. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.004 · Cited by 150
Hot spot-based design of small-molecule inhibitors for protein–protein interactions
Guo, W., Wisniewski, J. A., & Ji, H. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.095 · Cited by 148
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
Koes, D. R., Khoury, K., Huang, Y., Wang, W., Biśta, M., Popowicz, G. M., Wolf, S., Holak, T. A., Dömling, A. S. S., & Camacho, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032839 · Cited by 105
Self-citationA dimeric structure of PD-L1: functional units or evolutionary relics?
Chen, Y., Liu, P., Gao, F., Cheng, H. D., Qi, J., & Gao, G. F. (2010) · Protein & Cell · doi:10.1007/s13238-010-0022-1 · Cited by 77
Programmed cell death-1 inhibition in lymphoma
Hawkes, E. A., Grigg, A., & Chong, G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70103-8 · Cited by 75
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307906 · Cited by 72
Self-citationStructures of PD-1 with its ligands: Sideways and dancing cheek to cheek
Freeman, G. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805459105 · Cited by 63
Nivolumab for advanced squamous cell lung cancer: what are the next steps?
de Mello, R. A., Pousa, I. D., & Pereira, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70074-4 · Cited by 17
Multiple checkpoints on the long road towards cancer immunotherapy
Phan, T. G., Long, G. V., & Scolyer, R. A. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2015.12 · Cited by 11
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning
Gainza, P., Sverrisson, F., Monti, F., Rodolà, E., Boscaini, D., Bronstein, M. M., & Correia, B. E. (2020) · Nature Methods · doi:10.1038/s41592-019-0666-6 · Cited by 834
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Metadata
- Authors
- Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A.
- Venue
- Structure
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 23
- Issue
- 12
- Pages
- 2341-2348
- ISSN
- 0969-2126 (ISSN-L)
- OpenAlex
- W1749548564
- Cited by
- 531
- References
- 50
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.